Tenderwize
Back to tender search

Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination)

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 132 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

The procedure is explicitly not a public procurement under EU directive; legal challenges go to social courts, not proc...

Submission not via standard e-procurement portal; must be by email (with qualified electronic signature) or postal mail...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Enter into discount contracts for the drug combination Pertuzumab/Trastuzumab
  • No individual negotiations; uniform terms apply
Show full summary

Open-House procedure by multiple German health insurance funds (Techniker Krankenkasse, HEK, hkk) to conclude discount contracts for the drug combination Pertuzumab/Trastuzumab (Biologics) under §130c SGB V. No exclusivity; any qualified pharmaceutical entrepreneur may join during the contract period. Uniform conditions; no individual negotiations. Contract duration max 24 months (01.01.2025 - 31.12.2026). Early termination upon patent expiry.

Risks

The procedure is explicitly not a public procurement under EU directive; legal challenges go to social courts, not proc...

Submission not via standard e-procurement portal; must be by email (with qualified electronic signature) or postal mail...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG
  • Valid marketing authorization for the drug(s) or other legal basis for placing on the market
  • Company seat must be in Germany, EU, or EEA

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination)

Conclusion of discount contracts for Pertuzumab/Trastuzumab combination under §130c SGB V. Open to all qualified pharmaceutical entrepreneurs. Uniform contractual conditions, no exclusivity.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Dec 2024 - Dec 2026

Category

Pharmaceutical products

Deadline

Deadline Dec 31, 2026

Procurement Details

Publication date
13 Nov 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
694903-2024

Documents (1)

Procurement document 1

Similar tenders

Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)

Sep 15
1 SME lot

Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów

Sep 17

France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord

Sep 14
6 SME lots

Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)

Aug 27
3 framework lots3 SME lots

Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ

Sep 18

Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).

Sep 24